People with type 2 diabetes mellitus (T2DM) have a significantly higher risk of hearing loss (HL), according to a November study published in Otolaryngology–Head and Neck Surgery.

These findings highlight the potential of self-complementary AAVs to reduce dose requirements, minimize toxicity, and broaden clinical use of inner-ear therapies," said the head researcher.